Clinical Sequencing

News on sequencing-based testing, NGS gene panels, & diagnostic exomes in genetics, genomics, and molecular diagnostics.

The companies plan to offer a service called MyMap, which will include MyGenome next-generation sequencing by Veritas and MediMap pharmacogenomic testing by Inova.

Rainbow Genomics will offer exome-sequencing based screening and diagnostic tests developed by Baylor Genetics to patients in Asia.

Genome Medical will use the platform for ongoing examination of patients' genomic data to augment data analysis, annotation, and interpretation.

Next year, the company will submit regulatory filings for the drug in two molecularly defined indications and a next-generation sequencing companion diagnostic. 

The deal will open up more opportunities to study OmniSeq's 144-gene NGS test and Immune Report Card in real-world settings and as part of drug development trials.